

Álvaro Gonzalez-Cantero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1466225/publications.pdf>

Version: 2024-02-01

35
papers

401
citations

932766

10
h-index

794141

19
g-index

36
all docs

36
docs citations

36
times ranked

684
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". Journal of the American Academy of Dermatology, 2020, 83, 680-682.	0.6	136
2	Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (United States), 2017, 96, e6770.	0.4	41
3	Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI. PLoS ONE, 2018, 13, e0192663.	1.1	34
4	Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Journal of Investigative Dermatology, 2021, 141, 2402-2411.	0.3	27
5	Subclinical atherosclerosis in psoriasis. Usefulness of femoral artery ultrasound for the diagnosis, and analysis of its relationship with insulin resistance. PLoS ONE, 2019, 14, e0211808.	1.1	24
6	From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. International Journal of Molecular Sciences, 2021, 22, 6740.	1.8	16
7	Insulin resistance and NAFLD: Relationship with intrahepatic iron and serum TNF- α using 1H MR spectroscopy and MRI. Diabetes and Metabolism, 2019, 45, 473-479.	1.4	15
8	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. Journal of Dermatological Treatment, 2022, 33, 1661-1669.	1.1	15
9	Femoral artery ultrasound for improving the detection of atherosclerosis in psoriasis. Journal of the American Academy of Dermatology, 2019, 80, 784-786.	0.6	14
10	Women with moderate to severe psoriasis in Spain (<sc>BIOBADADERM</sc> registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population. British Journal of Dermatology, 2019, 181, 1085-1087.	1.4	14
11	Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts. European Journal of Preventive Cardiology, 2022, 29, 591-598.	0.8	9
12	Successful Treatment of Refractory Type 1 Pityriasis Rubra Pilaris With Apremilast. Journal of Cutaneous Medicine and Surgery, 2018, 22, 104-105.	0.6	8
13	Acute generalized exanthematous pustulosis (AGEP)-like contact dermatitis resulting from topical therapy in a polysensitized patient. Contact Dermatitis, 2019, 80, 329-333.	0.8	7
14	¿Existe variación en los diagnósticos dermatológicos entre la temporada de frío vs. calor? Un subanálisis del estudio DIADERM (España 2016). Actas Dermo-sifiliográficas, 2019, 110, 734-743.	0.2	7
15	Subcutaneous Sarcoidosis With Dactylitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 506-506.	0.6	6
16	Subclinical Liver Disease Is Associated with Subclinical Atherosclerosis in Psoriasis: Results from Two Observational Studies. Journal of Investigative Dermatology, 2022, 142, 88-96.	0.3	5
17	Fluorescence-advanced videodermoscopy characterization of demodex mites: a comparison with reflectance confocal microscopy. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e215-e216.	1.3	4
18	Pustular psoriasis of pregnancy managed with labor induction. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 259, 224-225.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. <i>Annals of Medicine</i> , 2021, 53, 1727-1736.	1.5	4
20	Comment on: "A Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patients" <i>American Journal of Clinical Dermatology</i> , 2017, 18, 709-711.	3.3	3
21	Advances of Genomic Medicine in Psoriatic Arthritis. <i>Journal of Personalized Medicine</i> , 2022, 12, 35.	1.1	3
22	"Nails Only" Phenotype and Partial Dominance of p.Glu170Lys Mutation in a Family with Epidermolysis Bullosa Simplex. <i>Pediatric Dermatology</i> , 2017, 34, e205-e206.	0.5	2
23	Complex regional pain syndrome of the face in a child. <i>International Journal of Dermatology</i> , 2018, 57, 1502-1503.	0.5	2
24	Is intima-media thickness a predictor for cardiovascular risk?. <i>Lancet, The</i> , 2019, 394, 380-381.	6.3	1
25	Psoriasis and subclinical atherosclerosis in a Chinese population. <i>Australasian Journal of Dermatology</i> , 2018, 59, e235-e236.	0.4	0
26	Apremilast en el tratamiento de la psoriasis, experiencia clínica real. <i>Piel</i> , 2018, 33, 144-145.	0.0	0
27	Metástasis cutáneas múltiples en tránsito de melanoma cutáneo. <i>Medicina Clínica</i> , 2018, 150, e45.	0.3	0
28	Relaciona a "Factores de riesgo cardiovascular y grosor de la íntima media carotídea en una población colombiana con psoriasis". <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 848-849.	0.2	0
29	Effect of Biologic Therapy on Cardiovascular Risk in Patients With Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 685-686.	0.2	0
30	Calciphylaxis in a kidney transplant patient. <i>Revista Clínica Española</i> , 2019, 219, 458-459.	0.3	0
31	Calcifilaxia en paciente trasplantado renal. <i>Revista Clínica Española</i> , 2019, 219, 458-459.	0.2	0
32	Psoriasis (S100A7) and koebserisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 234-234.	0.6	0
33	A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg. <i>Dermatologic Therapy</i> , 2020, 33, e13678.	0.8	0
34	FR- Tratamientos biológicos y su efecto en el riesgo cardiovascular de los pacientes con psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 685-686.	0.2	0
35	¿Cuál es el mejor método para medir el riesgo cardiovascular en pacientes con psoriasis?. <i>Piel</i> , 2019, 34, 449-451.	0.0	0